CA3015271C - Iminothiadiazinane dioxide derivatives as plasmepsin v inhibitors - Google Patents

Iminothiadiazinane dioxide derivatives as plasmepsin v inhibitors Download PDF

Info

Publication number
CA3015271C
CA3015271C CA3015271A CA3015271A CA3015271C CA 3015271 C CA3015271 C CA 3015271C CA 3015271 A CA3015271 A CA 3015271A CA 3015271 A CA3015271 A CA 3015271A CA 3015271 C CA3015271 C CA 3015271C
Authority
CA
Canada
Prior art keywords
formula
compound
chloro
compounds
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3015271A
Other languages
English (en)
French (fr)
Other versions
CA3015271A1 (en
Inventor
Teresa DE HARO GARCIA
Martin Alexander Lowe
Malcolm Maccoss
Richard David Taylor
Zhaoning Zhu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB Biopharma SRL
Original Assignee
UCB Biopharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCB Biopharma SRL filed Critical UCB Biopharma SRL
Publication of CA3015271A1 publication Critical patent/CA3015271A1/en
Application granted granted Critical
Publication of CA3015271C publication Critical patent/CA3015271C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA3015271A 2016-02-23 2017-02-22 Iminothiadiazinane dioxide derivatives as plasmepsin v inhibitors Active CA3015271C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1603104.9 2016-02-23
GBGB1603104.9A GB201603104D0 (en) 2016-02-23 2016-02-23 Therapeutic agents
PCT/EP2017/054023 WO2017144517A1 (en) 2016-02-23 2017-02-22 Iminothiadiazinane dioxide derivatives as plasmepsin v inhibitors

Publications (2)

Publication Number Publication Date
CA3015271A1 CA3015271A1 (en) 2017-08-31
CA3015271C true CA3015271C (en) 2023-08-01

Family

ID=55753038

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3015271A Active CA3015271C (en) 2016-02-23 2017-02-22 Iminothiadiazinane dioxide derivatives as plasmepsin v inhibitors

Country Status (10)

Country Link
US (1) US10464932B2 (https=)
EP (1) EP3419975B1 (https=)
JP (1) JP6831400B2 (https=)
CN (1) CN109153674B (https=)
BR (1) BR112018016196A2 (https=)
CA (1) CA3015271C (https=)
EA (1) EA034537B1 (https=)
ES (1) ES2886449T3 (https=)
GB (1) GB201603104D0 (https=)
WO (1) WO2017144517A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
GB201805816D0 (en) * 2018-04-06 2018-05-23 Ucb Biopharma Sprl Therapeutic agents
JP7640458B2 (ja) 2018-10-05 2025-03-05 アンナプルナ バイオ インコーポレイテッド Ａｐｊ受容体活性に関連する状態を処置するための化合物および組成物
CN110156608B (zh) * 2019-04-24 2022-04-01 深圳市第二人民医院 绿卡色林中间体对氯苯乙胺的合成方法
GB201906804D0 (en) 2019-05-14 2019-06-26 Ucb Biopharma Sprl Therapeutic agents
WO2021026884A1 (en) * 2019-08-15 2021-02-18 Merck Sharp & Dohme Corp. Antimalarial agents
CN114206856A (zh) * 2019-08-19 2022-03-18 Ucb生物制药有限责任公司 抗疟疾的六氢嘧啶类似物
WO2021155612A1 (en) * 2020-02-09 2021-08-12 Merck Sharp & Dohme Corp. Antimalarial agents
GB202010606D0 (en) 2020-07-10 2020-08-26 Ucb Biopharma Sprl Therapeutic agents
WO2023102747A1 (en) * 2021-12-07 2023-06-15 Merck Sharp & Dohme Llc Antimalarial agents
WO2023152042A1 (en) 2022-02-08 2023-08-17 UCB Biopharma SRL Antimalarial hexahydropyrimidine analogues

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006527201A (ja) * 2003-06-06 2006-11-30 スミスクライン・ビーチャム・コーポレイション Ｉｌ−８受容体アンタゴニスト
PT1699455E (pt) 2003-12-15 2013-08-27 Merck Sharp & Dohme Inibidores de protease de aspartilo heterocíclicos
US7763609B2 (en) * 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
UA108363C2 (uk) * 2009-10-08 2015-04-27 Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
HUE027946T2 (en) * 2010-01-18 2016-11-28 Medicines For Malaria Venture Mmv New anti-malaria drugs
WO2014093190A1 (en) 2012-12-14 2014-06-19 Merck Sharp & Dohme Corp. Bace inhibitors of iminothiadiazine dioxides

Also Published As

Publication number Publication date
ES2886449T3 (es) 2021-12-20
US10464932B2 (en) 2019-11-05
EA034537B1 (ru) 2020-02-18
CA3015271A1 (en) 2017-08-31
CN109153674B (zh) 2022-03-22
GB201603104D0 (en) 2016-04-06
JP6831400B2 (ja) 2021-02-17
JP2019509337A (ja) 2019-04-04
CN109153674A (zh) 2019-01-04
EP3419975A1 (en) 2019-01-02
US20190040053A1 (en) 2019-02-07
WO2017144517A1 (en) 2017-08-31
EA201891870A1 (ru) 2019-03-29
EP3419975B1 (en) 2021-06-23
BR112018016196A2 (pt) 2018-12-18

Similar Documents

Publication Publication Date Title
CA3015271C (en) Iminothiadiazinane dioxide derivatives as plasmepsin v inhibitors
US11136310B2 (en) Iminotetrahydropyrimidinone derivatives as plasmepsin V inhibitors
US11505532B2 (en) SSAO inhibitor
US9029392B2 (en) Quinoline derivatives as kinase inhibitors
US8487101B2 (en) Thieno-pyridine derivatives as MEK inhibitors
JP5243953B2 (ja) キナーゼ阻害剤としての縮合チアゾール誘導体
RS52824B (https=)
MX2013005242A (es) Derivados de farmacos.
WO2019101086A1 (zh) 卤代烯丙基胺类ssao/vap-1抑制剂及其应用
EP3398598B1 (en) Sulfonamide derivative and preparation method and use thereof
WO2010061180A1 (en) Quinoline derivatives as p13 kinase inhibitors
JP2022529311A (ja) Ｔｙｋ２偽キナーゼリガンド
CA2721576A1 (en) Compound having npy y5 receptor antagonist activity
JP5570981B2 (ja) キナーゼ阻害剤としての縮合チアゾール誘導体
KR20170032329A (ko) 피라졸 유도체의 제조 방법
JP2025505665A (ja) 抗マラリア性ヘキサヒドロピリミジン類似体
BR112018010473B1 (pt) Composto, composição farmacêutica e uso do composto

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20211115

H11 Ip right ceased following rejected request for revival

Free format text: ST27 STATUS EVENT CODE: T-6-6-H10-H11-H101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TIME LIMIT FOR REVERSAL EXPIRED

Effective date: 20250822

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20251107